The Primary Perspective: Bridging Gaps in Male Urologic and Cardiovascular Health

CME credit is offered upon successful completion of the posttest with a minimum score of 80% and submission of the evaluation after the activity.


RAPID REGISTRATION (TU MEMBERS)

If you are already a member of TestosteroneUpdate®, just enter your username and password below to autofill the registration form. Want to become a member? Click here



FULL REGISTRATION (NON-TU MEMBERS)

Please complete the form below to register for this activity. Your CME certificate will be issued from the following information.

* indicates a required field

Privacy Policy
We value the confidentiality of the information you choose to share with us and are committed to its protection. All personal information you provide is stored in a secure location and will never be sold or distributed to any third party.
PRETEST
Select the best answer to each question. All fields are required.
 
1 Approximately what percentage of your patients presenting with BPH/LUTS do you screen for hypogonadism?
 0% to 25%
 26% to 50%
 51% to 75%
 76% to 100%
 
2 In the United States, ______ PDE5 inhibitors are indicated for the treatment of ED and ______ is/are indicated for the treatment of BPH/LUTS.
 3; 1
 3; 2
 4, 1
 4, 2
 
3 Although preliminary results of recent studies suggest that normalizing testosterone levels in older men may positively affect IPSS and there is a lack of evidence supporting a causal relationship between exogenous testosterone and prostate cancer, the prescribing information for every testosterone therapy reinforces the need to ______.
 Monitor patients with BPH for worsening of signs and symptoms of BPH
 Evaluate patients for prostate cancer before initiating testosterone therapy and monitor during testosterone therapy
 Evaluate patients for symptoms of sexual dysfunction, including ejaculatory dysfunction and ED
 A and B
 
4 In the Shores 2012 observational cohort study following hypogonadal men who received testosterone therapy and those who remained untreated, the mortality rates were ______.
 Equal
 Lower in the treated group (10.3% versus 20.7%, untreated)
 Higher in the treated group (20.7% versus 10.3%, untreated)
 None of the above
 
5 Normalizing serum androgen levels with testosterone therapy appears to ______ prostate-tissue androgen levels and androgen-dependent cellular functions.
 Significantly increase
 Significantly decrease
 Have no effect on
 Have little effect on
© 2014 CogniMed Inc. All rights reserved.                           TU16001                           November 2014